HARDMAN & CO RESEARCH Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators

Transparency directive : regulatory news

17/09/2020 13:40

Hardman & Co Research
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators

17-Sep-2020 / 12:40 GMT/BST

Hardman & Co Research: Closely watching the regulators

Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) is being rolled out throughout Europe, and recent approvals in Israel and Australia will open up more markets. Later this month, attention will focus on the FDA, with the approaching PDUFA date for Alkindi. Next year should see the first approval of Chronocort in Europe. Based on current assumptions and expectations, Diurnal has sufficient cash through to profitability.

Please click on the link below for the full report:


If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
35 New Broad Street


Follow us on Twitter @HardmanandCo


Martin Hall

+44 20 7194 7622




Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

1133085  17-Sep-2020 


Other stories

28/09/2020 19:15
28/09/2020 17:48
28/09/2020 19:03
28/09/2020 18:24
28/09/2020 17:15
28/09/2020 18:06
28/09/2020 15:13
28/09/2020 15:24
28/09/2020 15:30
28/09/2020 13:50
28/09/2020 18:22
28/09/2020 09:07
28/09/2020 20:06
28/09/2020 05:06
28/09/2020 17:09
28/09/2020 15:53
28/09/2020 16:42
28/09/2020 17:41
28/09/2020 18:55
28/09/2020 15:00
28/09/2020 11:24
28/09/2020 13:01
28/09/2020 17:45
28/09/2020 12:00
28/09/2020 11:47
28/09/2020 14:56
28/09/2020 19:39
28/09/2020 18:02
28/09/2020 18:04
28/09/2020 19:16
28/09/2020 15:48
28/09/2020 18:36
28/09/2020 10:00
28/09/2020 12:56
27/09/2020 17:27
28/09/2020 17:13
28/09/2020 19:55
28/09/2020 17:25